Biomarker & Intervention Discovery

Stroke (Ischaemic / Cerebrovascular Disease)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

NIH funding$422MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionSpontaneous early neurological improvement in 10-20% within 24 hours of ischaemic stroke without intervention…
Best-intervention remissionIV thrombolysis (tPA/tenecteplase) within 4.5 hours: increases odds of favourable outcome by 30%; thrombectomy for…
Gap sizeVery large — enormous treatment gap; only 2-15% of eligible patients receive thrombolysis; <5% receive thrombectomy…
Primary barrieraccess/practice
Full remission profile →

Remission & chronicity

Spontaneous remission
Spontaneous early neurological improvement in 10-20% within 24 hours of ischaemic stroke without intervention; functional independence at 3 months in only 40-50% without revascularisation; 15% 30-day mortality untreated
Best-intervention remission
IV thrombolysis (tPA/tenecteplase) within 4.5 hours: increases odds of favourable outcome by 30%; thrombectomy for large vessel occlusion within 24 hours: 46% functional independence vs 27% control (DAWN/DEFUSE); combined thrombolysis + thrombectomy: best outcomes in eligible patients
Gap size
Very large — enormous treatment gap; only 2-15% of eligible patients receive thrombolysis; <5% receive thrombectomy worldwide
Primary barrier
access/practice
The 4.5-hour and 24-hour time windows are frequently missed due to delayed recognition, delayed presentation, or lack of stroke centre access; in-hospital treatment delays add further losses; secondary prevention (antihypertensives, statins, anticoagulation for AF) chronically underprescribed post-stroke
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-06.

No recent clinical trials found on ClinicalTrials.gov for this condition.


Agents Found By Disease-Level Search

Searched directly from “Stroke (Ischaemic / Cerebrovascular Disease)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 0-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.